Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
暂无分享,去创建一个
Wei-Sheng Huang | Jan Romero | Shuangying Liu | Tomi K Sawyer | Dong Zou | T. Clackson | V. Rivera | T. Zhou | T. Sawyer | W. Shakespeare | Frank Y Wang | Xiaotian Zhu | Frank Wang | Yaoyu Ning | Scott Wardwell | Yihan Wang | Mathew Thomas | Feng Li | John Iuliucci | Tim Clackson | Tianjun Zhou | R. Sundaramoorthi | David Wen | Chester A Metcalf | Ingrid Chen | Raji Sundaramoorthi | Jiwei Qi | Lisi Cai | Lois Commodore | Qihong Xu | Jeff Keats | Joseph T Snodgrass | Marc I Broudy | Karin Russian | Victor M Rivera | David C Dalgarno | William C Shakespeare | D. Dalgarno | J. Iuliucci | Jan Romero | K. Russian | M. Broudy | L. Commodore | Wei-sheng Huang | Yihan Wang | Xiaotian Zhu | C. Metcalf | Shuangying Liu | J. Keats | Scott D. Wardwell | Y. Ning | Qihong Xu | Jiwei Qi | D. Zou | Mathew P. Thomas | Feng Li | Lisi Cai | David Wen | I. Chen | Frank Y. Wang | J. Romero | Tianjun Zhou
[1] Wei-Sheng Huang,et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.
[2] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.
[3] Tomoko Niwa,et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. , 2007, Leukemia research.
[4] M. Avery,et al. Addition of lithioimidazoles to isocyanates followed by Pd-coupling: access to 4-substituted imidazole-2,5-dicarboxamides , 2004 .
[5] Rocco Piazza,et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[7] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[8] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[9] T. Clackson,et al. Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance , 2011, Chemical biology & drug design.
[10] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[11] N. Gray,et al. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. , 2010, Bioorganic & medicinal chemistry letters.
[12] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[13] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[14] G. Daley,et al. 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. , 2009, Journal of medicinal chemistry.